Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice
Ju Hwan Jeong(Chungbuk National University), Min‐Suk Song(Chungbuk National University), Seong Cheol Min(Chungbuk National University), Da Hyeon Kang(Chungbuk National University), Yun Hee Baek(Chungbuk National University), Ok-Jun Lee(Chungbuk National University Hospital), Yu Soo Yun(Chungbuk National University), Young Ki Choi(Institute for Basic Science), Santosh Chokkakula(Chungbuk National University), Beom Kyu Kim(Chungbuk National University), Won-Suk Choi(Chungbuk National University), Sol Oh(Chungbuk National University), Jang‐Hoon Choi(Korea National Institute of Health), Joo-Yeon Lee(Korea Disease Control and Prevention Agency), Eung‐Gook Kim(Chungbuk National University)
Cited by 82
Related Papers
Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19
|Scientific Reports|2020|99
Influenza Treatment: Limitations of Antiviral Therapy and Advantages of Drug Combination Therapy
|Microorganisms|2023|77
SARS-CoV-2 drug resistance and therapeutic approaches
|Heliyon|2025|44
Small molecules that allosterically inhibit p21-activated kinase activity by binding to the regulatory p21-binding domain
|Experimental & Molecular Medicine|2016|28
Molecular surveillance of antimicrobial resistance and transmission pattern of <i>Mycobacterium leprae</i> in Chinese leprosy patients
|Emerging Microbes & Infections|2019|22